Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb 4;86(3):1534-42.
doi: 10.1021/ac403044t. Epub 2014 Jan 17.

Quantification of therapeutic miRNA mimics in whole blood from nonhuman primates

Affiliations

Quantification of therapeutic miRNA mimics in whole blood from nonhuman primates

Kevin Kelnar et al. Anal Chem. .

Abstract

MRX34, a microRNA (miRNA)-based therapy for cancer, has recently entered clinical trials as the first clinical candidate in its class. It is a liposomal nanoparticle loaded with a synthetic mimic of the tumor suppressor miRNA miR-34a as the active pharmaceutical ingredient. To understand the pharmacokinetic properties of the drug and to rationalize an optimal dosing regimen in the clinic, a method is needed to quantitatively detect the miRNA mimic. Here, we report the development and qualification of a quantitative reverse transcription-polymerase chain reaction (qRT-PCR) assay in support of pharmacokinetic and toxicokinetic assessments in the nonhuman primate. Detection and quantification were performed on total ribonucleic acid (RNA) isolated from whole blood. The qualified range of the standard curve spans 6 orders of magnitude from 2.5 × 10(-7) to 2.5 × 10(-1) ng per reverse transcription (RT) reaction, corresponding to an estimated blood concentration from 6.2 × 10(-5) to 6.2 × 10(1) ng/mL. Our results demonstrate that endogenous as well as the exogenous miR-34a can be accurately and precisely quantified. The assay was used to establish the pharmacokinetic profile of MRX34, showing a favorable residence time and exposure of the miRNA mimic in whole blood from nonhuman primates.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pharmacokinetics of liposome-encapsulated miR-Rx34 in nonhuman primates. MRX34 was administered as a slow, intravenous bolus into a group of three nonhuman primates at a dose level of 1 mg/kg. Whole blood was collected at time points as indicated in the graph. Total RNA were isolated from 175 μL of whole blood per sample and eluted in 50 μL sterile, nuclease-free water. To ensure that miR-Rx34 concentrations are within the qualified range of the assay, RNA samples collected 1 min through 360 min post injection were diluted 1:10000. RNA samples collected 720 and 1440 min after administration of MRX34 were diluted 1:1000. RNA samples from untreated animals were diluted 1:10 to measure concentrations of endogenous miR-34a. For each qRT-PCR run, 2 μL of diluted RNA were used. Data are expressed as nanograms per milliter of blood.

References

    1. Bader A. G.; Brown D.; Winkler M. Cancer Res. 2010, 70, 7027–7030. - PMC - PubMed
    1. Esquela-Kerscher A.; Slack F. J. Nat. Rev. Cancer 2006, 6, 259–269. - PubMed
    1. Mirna Therapeutics. Mirna Therapuetics is First to Advance MicroRNA into the Clinic for Cancer. www.mirnarx.com (accessed May 13, 2013).
    1. Andreakos E.; Rauchhaus U.; Stavropoulos A.; Endert G.; Wendisch V.; Benahmed A. S.; Giaglis S.; Karras J.; Lee S.; Gaus H.; Bennett C. F.; Williams R. O.; Sideras P.; Panzner S. Arthritis Rheum. 2009, 60, 994–1005. - PubMed
    1. Bader A. G. Frontiers in Genetics 2012, 3, 120. - PMC - PubMed

Publication types